ABSTRACT

Immune Checkpoint Inhibitors, specifically anti PD-1 and anti PD-L1, are the foundation of immuno-oncology cancer treatment. Pembrolizumab was the first anti PD-1 approved by the FDA in 2014 for melanoma and in 2016 for patients with metastatic non small cell lung cancer (NSCLC). Though Pembrolizumab and other immune checkpoint inhibitor treatments have significantly improved overall survival versus chemotherapy in patients with NSCLC, the 5 year survival for metastatic NSCLC patients that were treated with pembrolizumab is only 32% while the median survival for patients treated with pembrolizumab for melanoma is 2 years. In the US today 43% of cancer patients diagnosed with solid tumors are eligible for immune checkpoint inhibitor treatment or approximately 850,000 patients annually, with a similar number of patients eligible for immune checkpoint inhibitors in Europe. The survival data noted for NSCLC and melanoma patients along with the substantial number of global cancer patients eligible for immune checkpoint inhibitors, demonstrate the significant unmet patient need that remains in cancer treatment.

T-Nanobio Therapeutics, is developing a new chemical entity, a bispecific nanoengager composed of two peptides that self-assemble in solution that target tumor and recruits effector immune cells. When combined with Pembrolizumab the results are cure in preclinical models. We incorporated in January of 2023 and are in the process of raising money to support manufacturing, Pharm/Tox studies and the conduct of a Phare I/II study in humans.

BIO

Dr. Maida is currently , Co-Founder, Chairman and CEO of T-NanoBioS Therapeutics, He currently serves as Consulting Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease where he is in the process of initiating and planning for eight (8) combination IIT trials with up to four major pharmaceutical firms. In addition, all eight studies incorporate a rigorous and thorough bioinformatic studies measuring up to close to 800 gene transcripts with the hopes of leading to an agnostic indication. Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., (9 years) a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. He is responsible for the oversight of the operations of the Company. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 25 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer. Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities. Over 30 plus years of clinical research in oncology Dr. Maida has worked with many of the “Centers of Excellence” and well as key opinion leaders (KOL) across many oncology indications. He is an expert in “virtual” development and cost-cutting of operations in large and small biotechnology companies. Dr. Maida has negotiated licensing agreements with a number of centers of excellence and premier pharmaceutical firms including but not limited to Eli Lilly, Novartis, RCT Corporation, Astra Zeneca, Pfizer, MD Anderson, Yale University, Stanford University, University of California San Francisco and Davis, the Wistar Institute, and Bristol Myers Squibb to mention a few. Over the past 18 years Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Dr. Maida was formerly the